Eurofins Scientific (ERF) Q4 2025 earnings summary

Executive summary

• Achieved or exceeded all FY 2025 objectives, including 24% EPS growth, 5% revenue growth, margin expansion, and strong free cash flow, confirming 2027 targets and marking progress in a five-year plan for a global digital laboratory network.

• Organic growth accelerated through the year, with Q4 showing the highest rate and EPS growth reaching 30% in the second half.

• Significant investments in automation, AI, IT, and infrastructure are driving improved operating leverage, with benefits from a five-year investment program starting to materialize.

• All regular capex and M&A investments were fully funded by operating cash flow, with surplus after investments.

• 2027 objectives reaffirmed, with further EBITDA margin and cash flow progress expected in 2026.

Financial highlights

• Revenues rose 5% year-over-year to €7,296m, with organic growth between 3.7% and 4.1%.

• Adjusted EBITDA increased 6% to €1,641m, margin up to 22.5%; reported EBITDA up 8% to €1,561m, margin at 21.4%.

• Basic EPS up 24% to €2.31; net profit up 17% to €473m.

• Free cash flow to the firm before investment in owned sites up 12% to €1,071m.

• Over €1.5bn returned to shareholders since 2021, including €540m in share buybacks in 2025.

Outlook and guidance

• FY 2026 targets mid-single-digit organic growth and €250m in annualized acquisition revenues.

• Adjusted EBITDA margin expected to improve further, with SDI at EBITDA level to decline.

• 2027 objectives reaffirmed: 6.5%+ organic growth, 24% adjusted EBITDA margin, SDI at 0.5% of revenues, and cash conversion above 50%.

• CapEx to remain around €400m/year, with €200m/year for owned sites in 2026–2027; major IT investments to wind down post-2027.

• Free cash flow and cash conversion expected to grow, supporting M&A and shareholder returns.